L-Dopa esters as potential prodrugs: behavioural activity in experimental models of Parkinson's disease
- 1 August 1987
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 39 (8) , 627-635
- https://doi.org/10.1111/j.2042-7158.1987.tb03441.x
Abstract
Intraperitoneal administration of the 2-tetrahydropyranylmethyl, phenoxyethyl, ethyl, 2-hydroxypropyl and methyl ester prodrugs of L-dopa produced locomotor activity in reserpine-pretreated mice with equal intensity and duration to that observed following administration of L-dopa itself. Administration of the 2-(1-methoxy)propyl ester produced a more prolonged effect while the p-methoxyphenylethyl, n-propyl, phenylethyl, m-trifluoromethylbenzyl, cyclohexyl, p-chlorophenylethyl and benzyl ester prodrugs were less active than L-dopa itself. On oral administration, the ethyl and methyl ester prodrugs were more effective than L-dopa in reversing reserpine-induced akinesia in mice. The 2-tetrahydropyranylmethyl, 2-(1-methoxy)propyl, 2-hydroxypropyl, n-propyl, benzyl and phenoxyethyl ester prodrugs produced effects comparable with those of L-dopa. In contrast, the cyclohexyl, m-trifluoromethylbenzyl, phenylethyl, p-chlorophenylethyl and p-methoxyphenylethyl ester prodrugs were less effective than L-dopa on oral administration. Intraperitoneal administration of L-dopa and the ester prodrugs of L-dopa to rats with a prior 6-hydroxydopamine (6-OHDA) lesion of the medial forebrain bundle (MFB) produced contraversive circling responses. Rotation observed following administration of the n-propyl, 2-tetrahydropyranylmethyl, methyl and ethyl ester prodrugs was more intense than that observed following administration of L-dopa itself. Rotation produced by the administration of L-dopa and the cyclohexyl, 2-(1-methoxy)propyl, phenylethyl, p-chlorophenylethyl, p-methoxyphenylethyl, benzyl, 2-hydroxypropyl, phenoxyethyl and m-trifluoromethylbenzyl ester prodrugs was identical. Ester prodrugs of L-dopa may be as effective as L-dopa itself in producing motor activity but overall none of the compounds tested was markedly more potent or of longer duration than L-dopa itself.This publication has 13 references indexed in Scilit:
- L-Dopa esters as potential prodrugs: behavioural activity in experimental models of Parkinson's diseaseJournal of Pharmacy and Pharmacology, 1987
- L-Dopa Methyl Ester—A Candidate for Chronic Systemic Delivery of L-Dopa in Parkinsonʼs DiseaseClinical Neuropharmacology, 1984
- ON-OFF FLUCTUATIONS IN PARKINSON'S DISEASEBrain, 1984
- COMPLICATED RESPONSE FLUCTUATIONS IN PARKINSON'S DISEASE: RESPONSE TO INTRAVENOUS INFUSION OF LEVODOPAThe Lancet, 1982
- Isolation and assay of noradrenaline, dopamine, 5-hydroxy-tryptamine, and several metabolites from brain tissue using disposable bio-rad columns packed with sephadex G-10Journal of Pharmacological Methods, 1978
- Improved delivery through biological membranes. 4. Prodrugs of L-DOPAJournal of Medicinal Chemistry, 1977
- Synthesis and antireserpine activity of peptides of L-dopaJournal of Medicinal Chemistry, 1974
- New Compounds: Synthesis of Alkyl Esters of D,L-DopaJournal of Pharmaceutical Sciences, 1973
- Biochemical and behavioral effects of l-DOPA methyl ester in cats treated with reserpinePsychopharmacology, 1965
- 3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine AntagonistsNature, 1957